Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)

NCT01502241 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT01502241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01502241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)
Lead sponsor
Heidelberg University
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
November 30, 2011
Enrollment
412 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma